June 11, 2008

FDA actions and shortcomings

Dr. Breggin’s educational campaigns and his scientific research contributed have put pressure on the FDA to change the contents of numerous FDA-approved labels for psychiatric drugs, including the neuroleptic (antipsychotic) drugs and the newer antidepressants.
Dr. Breggin’s articles about the FDA, especially the implications of recent label changes, can be found on this website in the section “The FDA: Articles, Critiques and Presentations .”
Dr. Breggin’s most complete analyses of the hand-in-glove relationships between the drug companies and the FDA can be found in the following three books:

Brain-Disabling Treatments in Psychiatry (2008)